These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36992500)

  • 1. Importance of Cellular Immunity and IFN-γ Concentration in Preventing SARS-CoV-2 Infection and Reinfection: A Cohort Study.
    Primorac D; Brlek P; Pavelić ES; Mešić J; Glavaš Weinberger D; Matišić V; Molnar V; Srića S; Zadro R
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal humoral and cell-mediated immune responses in a population-based cohort in Zurich, Switzerland between March and June 2022 - evidence for protection against Omicron SARS-CoV-2 infection by neutralizing antibodies and spike-specific T-cell responses.
    Zens KD; Llanas-Cornejo D; Menges D; Fehr JS; Münz C; Puhan MA; Frei A
    Int J Infect Dis; 2023 Aug; 133():18-26. PubMed ID: 37149211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
    Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
    Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade.
    Masiá M; Fernández-González M; García JA; Padilla S; García-Abellán J; Botella Á; Mascarell P; Agulló V; Gutiérrez F
    EBioMedicine; 2022 Aug; 82():104153. PubMed ID: 35816896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The serological IgG and neutralizing antibody of SARS-CoV-2 omicron variant reinfection in Jiangsu Province, China.
    Chu J; Dai Q; Dong C; Kong X; Tian H; Li C; Peng J; Xu K; Ju H; Bao C; Hu J; Zhu L
    Front Public Health; 2024; 12():1364048. PubMed ID: 38873290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
    Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
    Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular Immunity-The Key to Long-Term Protection in Individuals Recovered from SARS-CoV-2 and after Vaccination.
    Primorac D; Brlek P; Matišić V; Molnar V; Vrdoljak K; Zadro R; Parčina M
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection.
    Sedegah M; Porter C; Goguet E; Ganeshan H; Belmonte M; Huang J; Belmonte A; Inoue S; Acheampong N; Malloy AMW; Hollis-Perry M; Jackson-Thompson B; Ramsey KF; Alcorta Y; Maiolatesi SE; Wang G; Reyes AE; Illinik L; Sanchez-Edwards M; Burgess TH; Broder CC; Laing ED; Pollett SD; Villasante E; Mitre E; Hollingdale MR
    PLoS One; 2022; 17(10):e0276241. PubMed ID: 36251675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation.
    Azamor T; Horbach IS; Brito E Cunha D; Melgaço JG; Silva AMVD; Tubarão LN; Azevedo AS; Santos RT; Alves NDS; Machado TL; Silva J; Souza AF; Bayma C; Rocha VP; Frederico ABT; Dias BM; Setatino BP; Denani CB; Campos SPDC; Schwarcz WD; Sucupira MV; Mendes EP; Silva EDD; Barbosa de Lima SM; Ano Bom APD; Missailidis S
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior neutralizing response after first versus second SARS-CoV-2 infection in fully vaccinated individuals.
    Rivas G; Labiod N; Luczkowiak J; Lasala F; Rolo M; Mancheño-Losa M; Rial-Crestelo D; Lora-Tamayo J; Pérez-Rivilla A; Folgueira MD; Delgado R
    J Med Virol; 2023 Nov; 95(11):e29225. PubMed ID: 37971751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection.
    Schiffner J; Backhaus I; Rimmele J; Schulz S; Möhlenkamp T; Klemens JM; Zapf D; Solbach W; Mischnik A
    Front Public Health; 2021; 9():732787. PubMed ID: 34646805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 specific T-cell humoral response assessment after COVID-19 vaccination using a rapid direct real-time PCR amplification.
    Cosma C; Galla L; Padoan A; Furlan G; Marchioro L; Zaninotto M; Basso D; Plebani M
    Clin Chem Lab Med; 2023 Aug; 61(9):1652-1660. PubMed ID: 36957995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
    Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
    Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serological Markers of SARS-CoV-2 Reinfection.
    Siddiqui SM; Bowman KA; Zhu AL; Fischinger S; Beger S; Maron JS; Bartsch YC; Atyeo C; Gorman MJ; Yanis A; Hultquist JF; Lorenzo-Redondo R; Ozer EA; Simons LM; Talj R; Rankin DA; Chapman L; Meade K; Steinhart J; Mullane S; Siebert S; Streeck H; Sabeti P; Halasa N; Musk ER; Barouch DH; Menon AS; Nilles EJ; Lauffenburger DA; Alter G
    mBio; 2022 Feb; 13(1):e0214121. PubMed ID: 35073738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
    Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
    J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19.
    Kirchner T; Heinrich S; Bonifacius A; Engel B; Ruhl L; Pink I; Thomas N; Martens J; Hoeper MM; Blasczyk R; Wedemeyer H; Jaeckel E; Li Y; Falk CS; Eiz-Vesper B; Taubert R
    PLoS One; 2022; 17(11):e0276929. PubMed ID: 36322587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.
    Shiwa-Sudo N; Sakai Y; Iwata-Yoshikawa N; Watanabe S; Yamada S; Kuroda Y; Yamamoto T; Shirakura M; Fujisaki S; Miyazaki K; Miura H; Nagata S; Fukushi S; Maeda K; Hasegawa H; Suzuki T; Nagata N
    J Virol; 2023 Jan; 97(1):e0136622. PubMed ID: 36633406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response and severity of Omicron BA.5 reinfection among individuals previously infected with different SARS-CoV-2 variants.
    Li L; Xie Z; Li Y; Luo M; Zhang L; Feng C; Tang G; Huang H; Hou R; Xu Y; Jia S; Shi J; Fan Q; Gan Q; Yu N; Hu F; Li Y; Lan Y; Tang X; Li F; Deng X
    Front Cell Infect Microbiol; 2023; 13():1277880. PubMed ID: 38188634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.